Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors

Steven E Lipshultz, Lynn M. Anderson, Tracie L Miller, Mariana Gerschenson, Kristen E. Stevenson, Donna S. Neuberg, Vivian I. Franco, Daniel E. Libutti, Lewis B. Silverman, Lynda M. Vrooman, Stephen E. Sallan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND Impaired cardiac function in doxorubicin-treated childhood cancer survivors is partly mediated by the disruption of mitochondrial energy production. Doxorubicin intercalates into mitochondrial DNA (mtDNA) and disrupts genes encoding for polypeptides that make adenosine triphosphate. METHODS This cross-sectional study examined mtDNA copy numbers per cell and oxidative phosphorylation (OXPHOS) in peripheral blood mononuclear cells (PBMCs) in 64 childhood survivors of high-risk acute lymphoblastic leukemia (ALL) who had been treated on Dana-Farber Cancer Institute childhood ALL protocols and had received doxorubicin alone (42%) or doxorubicin with the cardioprotectant dexrazoxane (58%). The number of mtDNA copies per cell and the OXPHOS enzyme activity of nicotinamide adenine dinucleotide dehydrogenase (complex I [CI]) and cytochrome c oxidase (complex IV [CIV]) were measured with quantitative real-time polymerase chain reaction immunoassays and thin-layer chromatography, respectively. RESULTS At a median follow-up of 7.8 years after treatment, the median number of mtDNA copies per cell for patients treated with doxorubicin alone (1106.3) was significantly higher than the median number for those who had also received dexrazoxane (310.5; P =.001). No significant differences were detected between the groups for CI or CIV activity. CONCLUSIONS Doxorubicin-treated survivors had an increased number of PBMC mtDNA copies per cell, and concomitant use of dexrazoxane was associated with a lower number of mtDNA copies per cell. Because of a possible compensatory increase in mtDNA copies per cell to maintain mitochondrial function in the setting of mitochondrial dysfunction, overall OXPHOS activity was not different between the groups. The long-term sustainability of this compensatory response in these survivors at risk for cardiac dysfunction over their lifespan is concerning.

Original languageEnglish (US)
Pages (from-to)946-953
Number of pages8
JournalCancer
Volume122
Issue number6
DOIs
StatePublished - Mar 15 2016

Fingerprint

Dexrazoxane
Mitochondrial DNA
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doxorubicin
Survivors
Oxidative Phosphorylation
Blood Cells
Electron Transport Complex I
Electron Transport Complex IV
Thin Layer Chromatography
Immunoassay
NAD
Real-Time Polymerase Chain Reaction
Neoplasms
Cell Count
Cross-Sectional Studies
Adenosine Triphosphate
Peptides

Keywords

  • childhood cancer survivors
  • dexrazoxane
  • doxorubicin
  • mitochondrial DNA
  • mitochondrial function

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lipshultz, S. E., Anderson, L. M., Miller, T. L., Gerschenson, M., Stevenson, K. E., Neuberg, D. S., ... Sallan, S. E. (2016). Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer, 122(6), 946-953. https://doi.org/10.1002/cncr.29872

Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. / Lipshultz, Steven E; Anderson, Lynn M.; Miller, Tracie L; Gerschenson, Mariana; Stevenson, Kristen E.; Neuberg, Donna S.; Franco, Vivian I.; Libutti, Daniel E.; Silverman, Lewis B.; Vrooman, Lynda M.; Sallan, Stephen E.

In: Cancer, Vol. 122, No. 6, 15.03.2016, p. 946-953.

Research output: Contribution to journalArticle

Lipshultz, SE, Anderson, LM, Miller, TL, Gerschenson, M, Stevenson, KE, Neuberg, DS, Franco, VI, Libutti, DE, Silverman, LB, Vrooman, LM & Sallan, SE 2016, 'Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors', Cancer, vol. 122, no. 6, pp. 946-953. https://doi.org/10.1002/cncr.29872
Lipshultz SE, Anderson LM, Miller TL, Gerschenson M, Stevenson KE, Neuberg DS et al. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016 Mar 15;122(6):946-953. https://doi.org/10.1002/cncr.29872
Lipshultz, Steven E ; Anderson, Lynn M. ; Miller, Tracie L ; Gerschenson, Mariana ; Stevenson, Kristen E. ; Neuberg, Donna S. ; Franco, Vivian I. ; Libutti, Daniel E. ; Silverman, Lewis B. ; Vrooman, Lynda M. ; Sallan, Stephen E. / Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. In: Cancer. 2016 ; Vol. 122, No. 6. pp. 946-953.
@article{309957fd63e94dc6a8bbdf606ebe3eb6,
title = "Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors",
abstract = "BACKGROUND Impaired cardiac function in doxorubicin-treated childhood cancer survivors is partly mediated by the disruption of mitochondrial energy production. Doxorubicin intercalates into mitochondrial DNA (mtDNA) and disrupts genes encoding for polypeptides that make adenosine triphosphate. METHODS This cross-sectional study examined mtDNA copy numbers per cell and oxidative phosphorylation (OXPHOS) in peripheral blood mononuclear cells (PBMCs) in 64 childhood survivors of high-risk acute lymphoblastic leukemia (ALL) who had been treated on Dana-Farber Cancer Institute childhood ALL protocols and had received doxorubicin alone (42{\%}) or doxorubicin with the cardioprotectant dexrazoxane (58{\%}). The number of mtDNA copies per cell and the OXPHOS enzyme activity of nicotinamide adenine dinucleotide dehydrogenase (complex I [CI]) and cytochrome c oxidase (complex IV [CIV]) were measured with quantitative real-time polymerase chain reaction immunoassays and thin-layer chromatography, respectively. RESULTS At a median follow-up of 7.8 years after treatment, the median number of mtDNA copies per cell for patients treated with doxorubicin alone (1106.3) was significantly higher than the median number for those who had also received dexrazoxane (310.5; P =.001). No significant differences were detected between the groups for CI or CIV activity. CONCLUSIONS Doxorubicin-treated survivors had an increased number of PBMC mtDNA copies per cell, and concomitant use of dexrazoxane was associated with a lower number of mtDNA copies per cell. Because of a possible compensatory increase in mtDNA copies per cell to maintain mitochondrial function in the setting of mitochondrial dysfunction, overall OXPHOS activity was not different between the groups. The long-term sustainability of this compensatory response in these survivors at risk for cardiac dysfunction over their lifespan is concerning.",
keywords = "childhood cancer survivors, dexrazoxane, doxorubicin, mitochondrial DNA, mitochondrial function",
author = "Lipshultz, {Steven E} and Anderson, {Lynn M.} and Miller, {Tracie L} and Mariana Gerschenson and Stevenson, {Kristen E.} and Neuberg, {Donna S.} and Franco, {Vivian I.} and Libutti, {Daniel E.} and Silverman, {Lewis B.} and Vrooman, {Lynda M.} and Sallan, {Stephen E.}",
year = "2016",
month = "3",
day = "15",
doi = "10.1002/cncr.29872",
language = "English (US)",
volume = "122",
pages = "946--953",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors

AU - Lipshultz, Steven E

AU - Anderson, Lynn M.

AU - Miller, Tracie L

AU - Gerschenson, Mariana

AU - Stevenson, Kristen E.

AU - Neuberg, Donna S.

AU - Franco, Vivian I.

AU - Libutti, Daniel E.

AU - Silverman, Lewis B.

AU - Vrooman, Lynda M.

AU - Sallan, Stephen E.

PY - 2016/3/15

Y1 - 2016/3/15

N2 - BACKGROUND Impaired cardiac function in doxorubicin-treated childhood cancer survivors is partly mediated by the disruption of mitochondrial energy production. Doxorubicin intercalates into mitochondrial DNA (mtDNA) and disrupts genes encoding for polypeptides that make adenosine triphosphate. METHODS This cross-sectional study examined mtDNA copy numbers per cell and oxidative phosphorylation (OXPHOS) in peripheral blood mononuclear cells (PBMCs) in 64 childhood survivors of high-risk acute lymphoblastic leukemia (ALL) who had been treated on Dana-Farber Cancer Institute childhood ALL protocols and had received doxorubicin alone (42%) or doxorubicin with the cardioprotectant dexrazoxane (58%). The number of mtDNA copies per cell and the OXPHOS enzyme activity of nicotinamide adenine dinucleotide dehydrogenase (complex I [CI]) and cytochrome c oxidase (complex IV [CIV]) were measured with quantitative real-time polymerase chain reaction immunoassays and thin-layer chromatography, respectively. RESULTS At a median follow-up of 7.8 years after treatment, the median number of mtDNA copies per cell for patients treated with doxorubicin alone (1106.3) was significantly higher than the median number for those who had also received dexrazoxane (310.5; P =.001). No significant differences were detected between the groups for CI or CIV activity. CONCLUSIONS Doxorubicin-treated survivors had an increased number of PBMC mtDNA copies per cell, and concomitant use of dexrazoxane was associated with a lower number of mtDNA copies per cell. Because of a possible compensatory increase in mtDNA copies per cell to maintain mitochondrial function in the setting of mitochondrial dysfunction, overall OXPHOS activity was not different between the groups. The long-term sustainability of this compensatory response in these survivors at risk for cardiac dysfunction over their lifespan is concerning.

AB - BACKGROUND Impaired cardiac function in doxorubicin-treated childhood cancer survivors is partly mediated by the disruption of mitochondrial energy production. Doxorubicin intercalates into mitochondrial DNA (mtDNA) and disrupts genes encoding for polypeptides that make adenosine triphosphate. METHODS This cross-sectional study examined mtDNA copy numbers per cell and oxidative phosphorylation (OXPHOS) in peripheral blood mononuclear cells (PBMCs) in 64 childhood survivors of high-risk acute lymphoblastic leukemia (ALL) who had been treated on Dana-Farber Cancer Institute childhood ALL protocols and had received doxorubicin alone (42%) or doxorubicin with the cardioprotectant dexrazoxane (58%). The number of mtDNA copies per cell and the OXPHOS enzyme activity of nicotinamide adenine dinucleotide dehydrogenase (complex I [CI]) and cytochrome c oxidase (complex IV [CIV]) were measured with quantitative real-time polymerase chain reaction immunoassays and thin-layer chromatography, respectively. RESULTS At a median follow-up of 7.8 years after treatment, the median number of mtDNA copies per cell for patients treated with doxorubicin alone (1106.3) was significantly higher than the median number for those who had also received dexrazoxane (310.5; P =.001). No significant differences were detected between the groups for CI or CIV activity. CONCLUSIONS Doxorubicin-treated survivors had an increased number of PBMC mtDNA copies per cell, and concomitant use of dexrazoxane was associated with a lower number of mtDNA copies per cell. Because of a possible compensatory increase in mtDNA copies per cell to maintain mitochondrial function in the setting of mitochondrial dysfunction, overall OXPHOS activity was not different between the groups. The long-term sustainability of this compensatory response in these survivors at risk for cardiac dysfunction over their lifespan is concerning.

KW - childhood cancer survivors

KW - dexrazoxane

KW - doxorubicin

KW - mitochondrial DNA

KW - mitochondrial function

UR - http://www.scopus.com/inward/record.url?scp=84960342382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960342382&partnerID=8YFLogxK

U2 - 10.1002/cncr.29872

DO - 10.1002/cncr.29872

M3 - Article

C2 - 26762648

AN - SCOPUS:84960342382

VL - 122

SP - 946

EP - 953

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -